Search Result

Results for "

Analgesia

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (4) Adenosine Receptor (1) Adrenergic Receptor (9) Akt (2) Aminopeptidase (1) Apoptosis (4) Arrestin (1) ATP Synthase (4) Autophagy (4) Biochemical Assay Reagents (1) Calcium Channel (1) Cannabinoid Receptor (4) Carboxypeptidase (1) CGRP Receptor (2) Cholecystokinin Receptor (3) Cholinesterase (ChE) (2) COX (7) Cytochrome P450 (1) Dopamine Receptor (2) Drug Derivative (1) Endogenous Metabolite (4) Environmental Pollutants (1) FAAH (1) Ferroptosis (4) GABA Receptor (6) Glutathione Peroxidase (4) GlyT (2) iGluR (5) Insulin Receptor (2) Integrin (1) Interleukin Related (1) Isotope-Labeled Compounds (2) mAChR (3) MAGL (2) Mas-related G-protein-coupled Receptor (MRGPR) (1) mGluR (3) Mitophagy (4) MMP (3) Monoamine Oxidase (1) nAChR (1) Neprilysin (1) Neurokinin Receptor (2) Neuropeptide FF Receptor (3) Neurotensin Receptor (5) NF-κB (3) NOD-like Receptor (NLR) (4) Opioid Receptor (36) PGE synthase (1) Phosphodiesterase (PDE) (2) Phospholipase (1) PI3K (2) PINK1/Parkin (4) Potassium Channel (4) PPAR (1) Prostaglandin Receptor (1) Reactive Oxygen Species (ROS) (3) Reference Standards (15) Sigma Receptor (1) Sodium Channel (13) Taste Receptor (1) TNF Receptor (1) Trk Receptor (2) TRP Channel (7)
By Research Areas:	Cancer (17) Cardiovascular Disease (12) Endocrinology (2) Infection (4) Inflammation/Immunology (31) Metabolic Disease (14) Neurological Disease (115)
Click Chemistry:	Alkynes (1)

134

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-17034A

Dexmedetomidine hydrochloride Maximum Cited Publications 26 Publications Verification (+)-Medetomidine hydrochloride; (S)-Medetomidine hydrochloride	Adrenergic Receptor	Infection Cancer
Dexmedetomidine hydrochloride ((+)-Medetomidine hydrochloride) is a potent, selective and orally active agonist of α2-adrenoceptor, with a K_i of 1.08 nM. Dexmedetomidine hydrochloride shows 1620-fold selectivity against α1-adrenoceptor. Dexmedetomidine hydrochloride exhibits anxiolysis, sedation, and modest analgesia effects .

HY-12719

Dexmedetomidine Maximum Cited Publications 26 Publications Verification (+)-Medetomidine; (S)-Medetomidine	Adrenergic Receptor	Neurological Disease Cancer
Dexmedetomidine ((+)-Medetomidine) is a potent, selective and orally active agonist of α2-adrenoceptor, with a K_i of 1.08 nM. Dexmedetomidine shows 1620-fold selectivity against α1-adrenoceptor. Dexmedetomidine exhibits anxiolysis, sedation, and modest analgesia effects .

HY-15249

JZL 184 5+ Cited Publications	MAGL	Neurological Disease
JZL 184 is a potent, selective and irreversible MAGL inhibitor that blocks 2-Arachidonoylglycerol (2-AG) hydrolysis in brain membranes (IC₅₀ of 8 nM). JZL 184 displays >300-fold selectivity for MAGL over FAAH .

HY-90003

Tianeptine 1 Publications Verification	Opioid Receptor iGluR MMP PI3K Akt NF-κB	Neurological Disease Inflammation/Immunology
Tianeptine is an atypical antidepressant. Tianeptine is a moderate-intensity agonist of the μ-opioid receptor (MOR), and to a lesser extent, is an agonist of the δ-opioid receptor (DOR). Tianeptine is a glutamate modulator that can enhance AMPA receptor and antagonize NMDA receptor. tianeptine increases sensitivity of the α1 adrenergic receptor, which only manifests in chronic treatment. Tianeptine exerts neuroprotective effects under stress/inflammation-induced conditions, exhibiting anti-inflammatory and antioxidant properties. Tianeptine inhibits MMP-9 by suppressing the PI3K/Akt-mediated NF-κB pathway. Tianeptine can be used to alleviate symptoms of depression and anxiety, but does not cause sedative effects .

HY-113413

Imidazoleacetic acid 2 Publications Verification Imidazolyl-4-acetic acid	Endogenous Metabolite GABA Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease
Imidazoleacetic acid (Imidazolyl-4-acetic acid) is a blood-brain barrier-permeable full agonist of the GABA_A receptor. Imidazoleacetic acid forms via histamine oxidation in the mouse brain. Imidazoleacetic acid exerts multiple neurochemical and behavioral effects. Imidazoleacetic acid induces a range of centrally mediated effects, including analgesia, sedation, hypnosis, as well as reductions in blood pressure, body temperature, isolation-induced aggression and motor activity .

HY-N7126

Citronellal	Environmental Pollutants Potassium Channel	Neurological Disease
Citronellal is a monoterpene that can be found in the essential oils in various aromatic species of plants, with antiinflammatory and antinociceptive properties. Citronellal attenuates mechanical nociception, mediated in part by the NO-cGMP-ATP-sensitive K+ channel pathway. Citronellal induces reduction of spontaneuous activity, ataxia, analgesia, and sedation in vivo. Citronellal can attenuate mechanical nociception response in mouse model .

HY-A0082

Diphenidol hydrochloride Difenidol hydrochloride	mAChR Sodium Channel	Neurological Disease
Diphenidol hydrochloride (Difenidol hydrochloride) is a non-selective muscarinic M₁-M₄ receptor antagonist, has anti-arrhythmic activity. Diphenidol hydrochloride is also a potent non-specific blocker of voltage-gated ion channels (Na ⁺, K ⁺, and Ca ²⁺) in neuronal cells. Diphenidol hydrochloride can be used in the study of antivertigo and antinausea .

HY-14785

Befiradol NLX-112; F13640	5-HT Receptor	Neurological Disease
Befiradol (NLX-112) is a highly selective 5-HT₁A receptor agonist that acts on both presynaptic and postsynaptic sites. Befiradol attenuates fentanyl-induced respiratory depression in neonatal and adult rats. Befiradol reduces the duration of fentanyl-induced analgesia and sedation in adult rats. Befiradol can be used in studies related to opioid-induced respiratory depression .

HY-106840

L-365260 2 Publications Verification	Cholecystokinin Receptor	Neurological Disease Metabolic Disease
L-365260 is an orally active and selective antagonist of non-peptide gastrin and brain cholecystokinin receptor (CCK-B), with K_is of 1.9 nM and 2.0 nM, respectively. L-365260 interacts in a stereoselective and competitive manner with guinea pig stomach gastrin and brain CCK receptors. L-365260 can enhance Morphine analgesia and prevents Morphine tolerance .

HY-90003A

Tianeptine sodium salt 1 Publications Verification	Opioid Receptor iGluR MMP PI3K Akt NF-κB	Neurological Disease Inflammation/Immunology
Tianeptine sodium salt is an atypical antidepressant. Tianeptine sodium salt is a moderate-intensity agonist of the μ-opioid receptor (MOR), and to a lesser extent, is an agonist of the δ-opioid receptor (DOR). Tianeptine sodium salt is a glutamate modulator that can enhance AMPA receptor and antagonize NMDA receptor. Tianeptine sodium salt increases sensitivity of the α1 adrenergic receptor, which only manifests in chronic treatment. Tianeptine sodium salt exerts neuroprotective effects under stress/inflammation-induced conditions, exhibiting anti-inflammatory and antioxidant properties. Tianeptine sodium salt inhibits MMP-9 by suppressing the PI3K/Akt-mediated NF-κB pathway. Tianeptine sodium salt can be used to alleviate symptoms of depression and anxiety, but does not cause sedative effects .

HY-119104

AZD1940 1 Publications Verification	Cannabinoid Receptor	Neurological Disease
AZD1940 is an orally active, high affinity cannabinoid CB1/CB2 receptor agonist with pK_i values of 7.93 and 9.06 for human CB1R and CB2R, respectively. AZD1940 shows a robust analgesia action .

HY-153935

EP4-IN-1	Prostaglandin Receptor	Inflammation/Immunology Cancer
EP4-IN-1 is a potent prostanoid EP4 receptor inhibitor. EP4-IN-1 is extracted from patent WO2023025270 (example 1), and exhibits prospect in tumor immunity and anti-inflammatory analgesia research .

HY-108707

LY3130481 1 Publications Verification	iGluR	Neurological Disease
LY3130481 is an orally available AMPA receptor antagonist, selectively inhibiting the IC₅₀ value of AMPA/TARP γ-8 at 65 nM. LY3130481 has anticonvulsant, antiepileptic, and pain-relieving effects .

HY-118120

GEMSA 2-Guanidinoethylmercaptosuccinic acid	Carboxypeptidase	Neurological Disease
GEMSA is a potent inhibitor of enkephalin convertase (K_i=8.8 nM). GEMSA elicites analgesia .

HY-12719R

Dexmedetomidine (Standard) (+)-Medetomidine (Standard); (S)-Medetomidine (Standard)	Reference Standards Adrenergic Receptor	Neurological Disease Cancer
Dexmedetomidine (Standard) is the analytical standard of Dexmedetomidine. This product is intended for research and analytical applications. Dexmedetomidine ((+)-Medetomidine) is a potent, selective and orally active agonist of α2-adrenoceptor, with a K_i of 1.08 nM. Dexmedetomidine shows 1620-fold selectivity against α1-adrenoceptor. Dexmedetomidine exhibits anxiolysis, sedation, and modest analgesia effects .

HY-B1288A

Oxybuprocaine Benoxinate; Novesinol; Oxybucaine	Sodium Channel	Cardiovascular Disease Neurological Disease
Oxybuprocaine is a short-acting ester anesthetic. Oxybuprocaine binds to sodium channels and reversibly stabilizes neuronal membranes. Oxybuprocaine has cutaneous analgesic properties. Oxybuprocaine is less potent than Bupivacaine (HY-B0405) at producing central nervous system and cardiovascular toxicity. Oxybuprocaine can be used in ophthalmology and otolaryngology .

HY-15249R

JZL 184 (Standard)	MAGL Reference Standards	Neurological Disease
JZL 184 (Standard) is the analytical standard of JZL 184. This product is intended for research and analytical applications. JZL 184 is a potent, selective and irreversible MAGL inhibitor that blocks 2-Arachidonoylglycerol (2-AG) hydrolysis in brain membranes (IC50 of 8 nM). JZL 184 displays >300-fold selectivity for MAGL over FAAH .

HY-122964

URB447	Cannabinoid Receptor	Metabolic Disease
URB447 is a peripherally restricted CB₁ cannabinoid antagonist (IC₅₀: 313 nM and 41 nM for rat CB1 and human CB2 receptor respectively ). URB447 lowers food intake and body-weight gain in mice without entering the brain or antagonizing central CB₁-dependent responses. URB447 can be used for research of obesity .

HY-17034AR

Dexmedetomidine hydrochloride (Standard) (+)-Medetomidine hydrochloride (Standard); (S)-Medetomidine hydrochloride (Standard)	Reference Standards Adrenergic Receptor	Neurological Disease Endocrinology Cancer
Dexmedetomidine (hydrochloride) (Standard) is the analytical standard of Dexmedetomidine (hydrochloride). This product is intended for research and analytical applications. Dexmedetomidine hydrochloride ((+)-Medetomidine hydrochloride) is a potent, selective and orally active agonist of α2-adrenoceptor, with a K_i of 1.08 nM. Dexmedetomidine hydrochloride shows 1620-fold selectivity against α1-adrenoceptor. Dexmedetomidine hydrochloride exhibits anxiolysis, sedation, and modest analgesia effects .

HY-W000665

2,6-Dimethyl-L-tyrosine Dmt	Opioid Receptor	Neurological Disease
2,6-Dimethyl-L-tyrosine (Dmt) is a tyrosine derivative that enhances receptor affinity, functional bioactivity and in vivo analgesia of opioid peptides .

HY-107527

Org 25543 hydrochloride	GlyT	Neurological Disease
Org 25543 hydrochloride is a selective and irreversible GlyT2 inhibitor (IC₅₀: 16 nM). Org 25543 hydrochloride has analgesia effect. Org 25543 hydrochloride ameliorates mechanical allodynia after partial sciatic nerve ligation injury in mice .

HY-P3087

Tyr-W-MIF-1	Opioid Receptor	Neurological Disease
Tyr-W-MIF-1 is an opioid tetrapeptide with opiate and antiopiate activity. Tyr-W-MIF-1 can induce analgesia .

HY-107743

Naloxone benzoylhydrazone NalBzoH	Opioid Receptor	Neurological Disease
Naloxone benzoylhydrazone (NalBzoH) is a mixed agonist/antagonist. Naloxone benzoylhydrazone is a prototypic κ3-opioid receptor agonist, and a partial agonist at the cloned μ and δ opioid receptors, and an antagonist at opioid-like NOP receptors. Naloxone benzoylhydrazone has potently analgesia effect .

HY-19057

Vatinoxan 2 Publications Verification MK-467; L-659066	Adrenergic Receptor	Cardiovascular Disease Neurological Disease
Vatinoxan (MK-467) is an alpha 2-adrenergic receptor antagonist. The peripheral selectivity of Vatinoxan determines that it has limited penetration across the blood-brain barrier and therefore has low concentrations in the central nervous system. Vatinoxan antagonizes alpha 2-adrenergic receptor receptors by binding to them, thereby reducing or preventing cardiovascular effects caused by α2-adrenergic agonists. Vatinoxan can be used in studies of cardiovascular effects, sedation and analgesia .

HY-107664A

SR 142948 dihydrochloride	Neurotensin Receptor	Neurological Disease
SR 142948 dihydrochloride is an orally active and selective non-peptide neurotensin receptor (NT) antagonist with IC₅₀s of 1.19 nM, 0.32 nM, 3.96 nM in h-NTR1-CHO cells, HT-29 cells, and adult rat brain, respectively. SR 142948 dihydrochloride antagonizes NT-induced inositol monophosphate formation in HT-29 cells with an IC₅₀ of 3.9 nM. SR 142948 dihydrochloride blocks hypothermia, analgesia and steering behavior induced by NT in vivo. SR 142948 dihydrochloride shows blood-brain permeability and can be used in study of psychiatric disorders .

HY-N6891

Hamaudol 2 Publications Verification	COX	Inflammation/Immunology
Hamaudol is a chromone isolated from Saposhnikovia divaricata. Hamaudol shows significant inhibitory activity on cyclooxygenase (COX)-1 and COX-2 activities with IC₅₀ values of 0.30, 0.57 mM, respectively, and has potent analgesia and anti-inflammary effects .

HY-106840A

L-365260 hemihydrate 2 Publications Verification	Cholecystokinin Receptor	Neurological Disease Metabolic Disease
L-365260 hemihydrate is an orally active and selective antagonist of non-peptide gastrin and brain cholecystokinin receptor (CCK-B), with K_is of 1.9 nM and 2.0 nM, respectively. L-365260 hemihydrate interacts in a stereoselective and competitive manner with guinea pig stomach gastrin and brain CCK receptors .

HY-W251708

AHR 10240	Endogenous Metabolite	Neurological Disease
AHR 10240, a cyclic amide, is a metabolite of Bromfenac (HY-B1888). AHR 10240 can be used for analgesia research

HY-115823

ztz240	Potassium Channel	Neurological Disease
ztz240 is a chemical modulator of voltage-gated potassium channel Kv7 (KCNQ) (KCNQ2 and 3: EC₅₀=6.1 μM; KCNQ4: EC₅₀=12.2 μM). ztz240 can be used in analgesia and anti-epileptic research .

HY-P2046

β-Endorphin (rat)	Opioid Receptor	Neurological Disease
β-Endorphin (rat) is an endogenous opioid neuropeptide and peptide hormone. β-Endorphin (rat) has analgesic activity and also contributes to food intake in satiated rats. β-Endorphin (rat) can be used in the research of neurological diseases such as analgesia and drug addiction .

HY-168997

CB1R agonist 1	Cannabinoid Receptor	Neurological Disease Inflammation/Immunology
CB1R agonist 1 is a potent, CNS-penetrant, and selective Cannabinoid-1 receptor (CB1R) agonist with a Ki of 0.95 nM, modulating G_i/o signaling. CB1R agonist 1 exhibits high selectivity over CB2R and other off-target GPCRs, including GPR55, GPR18, and GPR119. CB1R agonist 1 induces analgesia and hypothermia, and potentiates opioid analgesia in mice. CB1R agonist 1 can be used for the research of pain .

HY-111097

AF3442	PGE synthase	Neurological Disease Inflammation/Immunology
AF3442 is a potent and selective mPGES-1 inhibitor (IC₅₀ = 0.06 μM) which reduces monocyte PGE₂ generation also in the presence of plasma proteins. AF3442 shows selectivity over other prostanoids (TXB₂, PGF_2α and 6-keto-PGF_1α). AF3442 can be used for research in analgesia .

HY-124744

ASP 8477	FAAH	Neurological Disease
ASP 8477 is an orally active and selective fatty acid amide hydrolase (FAAH) inhibitor with IC₅₀ values of 3.99, 1.65, and 57.3 nM for human FAAH-1, FAAH-1 (P129T), and FAAH-2, respectively. ASP 8477 has central nervous system activity and can be used in analgesia research .

HY-169469

N-Phenethylnoroxymorphone	Opioid Receptor	Neurological Disease
N-Phenethylnoroxymorphone is an opioid compound. N-Phenethylnoroxymorphone enhances morphine-induced analgesia in rats. N-Phenethylnoroxymorphone can be used for research on neurological diseases .

HY-P10395

DP50	Opioid Receptor Neuropeptide FF Receptor	Neurological Disease
DP50 is a bifunctional compound that contains an opioid receptor (MOP) agonist and a neuropeptide FF receptor (NPFFR) antagonist. DP50 can be used in analgesia-related research .

HY-P10394

DP32	Opioid Receptor Neuropeptide FF Receptor	Neurological Disease
DP32 is a bifunctional compound that contains an opioid receptor (MOP) agonist and a neuropeptide FF receptor (NPFFR) antagonist. DP32 can be used in analgesia-related research .

HY-P1198

Hemokinin 1, human	Neurokinin Receptor	Neurological Disease
Hemokinin 1, human is a selective tachykinin neurokinin 1 (NK1) receptor full agonist. Hemokinin 1, human is a full agonist at NK2 and NK3 receptor. Hemokinin 1, human can produces an opioid-independent analgesia .

HY-B0718

Methoxyflurane DA-759	Potassium Channel	Neurological Disease
Methoxyflurane disrupts neuronal transmission by interfering with the release and re-uptake of neurotransmitters at post-synaptic terminals, or altering ionic conductance following receptor activation . Methoxyflurane is an analgesic agent that provides rapid short-term analgesia. Methoxyflurane may shows a effective non-opioid treatment option for trauma pain .

HY-P991622

MNAC13	Trk Receptor	Neurological Disease Inflammation/Immunology
MNAC13 is a kind of mouse IgG1 chimeric antibody, targeting to human TrkA. MNAC13 inhibits the NGF dependent signaling pathway by specifically binding to TrkA receptors. MNAC13 has good analgesic effect and long-lasting efficacy. MNAC13 can be used for researches on inflammatory and chronic pain .

HY-14785A

Befiradol hydrochloride NLX-112 hydrochloride; F 13640 hydrochloride	5-HT Receptor	Neurological Disease Metabolic Disease
Befiradol (NLX-112) hydrochloride is a highly selective 5-HT₁A receptor agonist that acts on both presynaptic and postsynaptic sites. Befiradol hydrochloride attenuates fentanyl-induced respiratory depression in neonatal and adult rats. Befiradol reduces the duration of fentanyl-induced analgesia and sedation in adult rats. Befiradol hydrochloride can be used in studies related to opioid-induced respiratory depression .

HY-163667

Atoxifent	Opioid Receptor	Neurological Disease
Atoxifent is a potent μ-opioid receptor agonist (EC₅₀=0.39 nM). These receptors are found in brain regions that control pain, emotions, habitual learning, and cognition. Atoxifent exhibits strong analgesic effects and a lower risk of respiratory depression. Atoxifent can be used for research in opioid pharmacology and signal transduction .

HY-17034AS

Dexmedetomidine-13C,d3 hydrochloride (+)-Medetomidine-13C,d3 hydrochloride; (S)-Medetomidine-13C,d3 hydrochloride	Isotope-Labeled Compounds Adrenergic Receptor	Neurological Disease Endocrinology Cancer
Dexmedetomidine- ¹³C,d₃ (hydrochloride) is the ¹³C- and deuterium labeled Dexmedetomidine (hydrochloride). Dexmedetomidine hydrochloride ((+)-Medetomidine hydrochloride) is a potent, selective and orally active agonist of α2-adrenoceptor, with a K_i of 1.08 nM. Dexmedetomidine hydrochloride shows 1620-fold selectivity against α1-adrenoceptor. Dexmedetomidine hydrochloride exhibits anxiolysis, sedation, and modest analgesia effects .

HY-A0270

Diphenidol	mAChR Sodium Channel	Neurological Disease
Diphenidol is a non-selective muscarinic M₁-M₄ receptor antagonist, has anti-arrhythmic activity. Diphenidol is also a potent non-specific blocker of voltage-gated ion channels (Na ⁺, K ⁺, and Ca ²⁺) in neuronal cells. Diphenidol can be used in the study of antivertigo and antinausea .

HY-163917

SalA-VS-08	Opioid Receptor	Neurological Disease
SalA-VS-08 is a full agonist of kappa-opioid receptor (KOR) with selectivity and G-protein bias. SalA-VS-08 can be used in the research of analgesia .

HY-172979

DH-1-106	Opioid Receptor	Neurological Disease
DH-1-106 is a MOR partial agonist. DH-1-106 can be used in the study of analgesia .

HY-P2199

SNF 9007	Opioid Receptor	Neurological Disease
SNF 9007 is a cholecystokinin analog. SNF 9007 induces analgesia by acting on δ-1, δ-2, and μ opioid receptors in the mouse brain .

HY-159634

Zidometacin	COX	Inflammation/Immunology
Zidometacin is a nonsteroidal anti-inflammatory agent. Zidometacin significantly inhibits prostaglandin synthesis with low gastrolesive influence. Zidometacin has antinociceptive and antipyretic activities and shows relatively low ulcerogenicity in rat models. Zidometacin can be used for analgesia and osteoarthritis research .

HY-106887

SCH 32615	Neprilysin	Neurological Disease
SCH 32615 is an enkephalinase (the enzymes responsible for the degradation of endogenous enkephalins) inhibitor. SCH 32615 can enhance surgery- and pregnancy-induced analgesia in mice .

HY-P2579

Dafphedyn	Opioid Receptor	Neurological Disease Metabolic Disease
Dafphedyn is an analogue of Dynorphin (1-13). Dafphedyn has diuretic and profound analgesia effects that can be antagonized by centrally administered Naltrexone (HY-76711) or Naloxone (HY-17417A) .

HY-P5892

β-Endorphin (1-27) (human)	Opioid Receptor	Neurological Disease
β-Endorphin (1-27) (human) is an opioid antagonist that binds μ-, δ-, and κ-opioid receptors with K_is of 5.31, 6.17, and 39.82 nM, respectively. β-Endorphin (1-27) (human) inhibits β-Endorphin (HY-P1502)-induced and etorphine-induced analgesia .

Cat. No.	상품명	Target	Research Area

HY-107663A

MIF-1 TFA Pro-Leu-Gly-NH2 TFA; Melanostatin TFA	Dopamine Receptor	Neurological Disease
MIF-1 TFA (Melanostatin), an endogenous brain peptide, is a potent dopamine receptor allosteric modulator. MIF-1 TFA inhibits melanin formation. MIF-1 TFA blocks the effects of opioid receptor activation to modulate the analgesic effects. MIF-1 TFA accesses from the blood to the CNS by directly crossing the blood-brain barrier (BBB) .

HY-P1248

Neuropeptide FF NPFF	Neuropeptide FF Receptor	Cardiovascular Disease Neurological Disease
Neuropeptide FF (NPFF), an octapeptide belonging to the RF-amide family of peptides, is a NPFF1 and NPFF2 receptors agonist with K_i values of 2.82 nM and 0.21 nM, respectively. Neuropeptide FF induces abstinence syndrome, exerts antiopioid and analgesic effects, releases via calcium-dependent mechanisms from rat spinal cord, regulates memory, autonomic function, and neuroendocrine function, modulates pain and opioid antinociception, reduces food intake, stimulates water intake, alters cardiovascular parameters, and shows differential activity in hypothalamic paraventricular nucleus neurons. Neuropeptide FF is present in mammalian central nervous system and periphery, with NPFF-immunoreactivity increases in rat cerebrospinal fluid during opiate tolerance, and its NPFF gene and NPFF-R2 gene are up-regulated in rat spinal cord and dorsal root ganglia during peripheral inflammation. Neuropeptide FF can be used for the research of opioid tolerance, morphine-induced analgesia, abstinence syndrome, pain, hypertension, nociception, inflammatory pain, and neuropathic pain .

HY-P3538

Corticotropin-releasing factor (Sheep) CRH (Sheep)	Peptides	Neurological Disease
Corticotropin-releasing factor (CRH) (Sheep) is a brain-penetrant hypothalamic releasing factor and a peptide hormone with analgesic and arousal-inducing activity. Corticotropin-releasing factor (Sheep) mediates stress effects, including stress-induced analgesia. Corticotropin-releasing factor (Sheep) increases wakefulness, reduces slow wave sleep, alters EEG frequency content, stimulates ACTH and β-endorphin release, activates locomotor activity. Corticotropin-releasing factor (Sheep) can be used for the research of neurological disease .

HY-P1329A

CTOP TFA 1 Publications Verification	Opioid Receptor	Neurological Disease
CTOP TFA is a potent and highly selective μ-opioid receptor antagonist. CTOP TFA antagonizes the acute analgesic effect and hypermotility. CTOP TFA enhances extracellular dopamine levels in the nucleus accumbens. CTOP TFA dose-dependently enhances locomotor activity .

HY-W000665

2,6-Dimethyl-L-tyrosine Dmt	Opioid Receptor	Neurological Disease
2,6-Dimethyl-L-tyrosine (Dmt) is a tyrosine derivative that enhances receptor affinity, functional bioactivity and in vivo analgesia of opioid peptides .

HY-107663

MIF-1 Pro-Leu-Gly-NH2; Melanostatin	Dopamine Receptor	Neurological Disease
MIF-1 (Melanostatin), an endogenous brain peptide, is a potent dopamine receptor allosteric modulator. MIF-1 inhibits melanin formation. MIF-1 blocks the effects of opioid receptor activation to modulate the analgesic effects. MIF-1 accesses from the blood to the CNS by directly crossing the blood-brain barrier (BBB) .

HY-P3087

Tyr-W-MIF-1	Opioid Receptor	Neurological Disease
Tyr-W-MIF-1 is an opioid tetrapeptide with opiate and antiopiate activity. Tyr-W-MIF-1 can induce analgesia .

HY-P1329

CTOP	Opioid Receptor	Neurological Disease
CTOP is a potent and highly selective μ-opioid receptor antagonist. CTOP antagonizes the acute morphine-induced analgesic effect and hypermotility. CTOP enhances extracellular dopamine levels in the nucleus accumbens. CTOP dose-dependently enhances locomotor activity .

HY-P2046

β-Endorphin (rat)	Opioid Receptor	Neurological Disease
β-Endorphin (rat) is an endogenous opioid neuropeptide and peptide hormone. β-Endorphin (rat) has analgesic activity and also contributes to food intake in satiated rats. β-Endorphin (rat) can be used in the research of neurological diseases such as analgesia and drug addiction .

HY-P10395

DP50	Opioid Receptor Neuropeptide FF Receptor	Neurological Disease
DP50 is a bifunctional compound that contains an opioid receptor (MOP) agonist and a neuropeptide FF receptor (NPFFR) antagonist. DP50 can be used in analgesia-related research .

HY-P10394

DP32	Opioid Receptor Neuropeptide FF Receptor	Neurological Disease
DP32 is a bifunctional compound that contains an opioid receptor (MOP) agonist and a neuropeptide FF receptor (NPFFR) antagonist. DP32 can be used in analgesia-related research .

HY-P1198

Hemokinin 1, human	Neurokinin Receptor	Neurological Disease
Hemokinin 1, human is a selective tachykinin neurokinin 1 (NK1) receptor full agonist. Hemokinin 1, human is a full agonist at NK2 and NK3 receptor. Hemokinin 1, human can produces an opioid-independent analgesia .

HY-P1319

Nociceptin(1-7)	Opioid Receptor	Inflammation/Immunology
Nociceptin (1-7) is the N-terminal bioactive fragment of nociceptin (HY-P0183). Nociceptin (1-7) is a potent ORL₁ (NOP) receptor agonist with antinociceptive activity. Nociceptin (1-7) combines with nociceptin reduces hyperalgesia in vivo .

HY-P2199

SNF 9007	Opioid Receptor	Neurological Disease
SNF 9007 is a cholecystokinin analog. SNF 9007 induces analgesia by acting on δ-1, δ-2, and μ opioid receptors in the mouse brain .

HY-P2579

Dafphedyn	Opioid Receptor	Neurological Disease Metabolic Disease
Dafphedyn is an analogue of Dynorphin (1-13). Dafphedyn has diuretic and profound analgesia effects that can be antagonized by centrally administered Naltrexone (HY-76711) or Naloxone (HY-17417A) .

HY-P5892

β-Endorphin (1-27) (human)	Opioid Receptor	Neurological Disease
β-Endorphin (1-27) (human) is an opioid antagonist that binds μ-, δ-, and κ-opioid receptors with K_is of 5.31, 6.17, and 39.82 nM, respectively. β-Endorphin (1-27) (human) inhibits β-Endorphin (HY-P1502)-induced and etorphine-induced analgesia .

HY-P1338

PL-017	Opioid Receptor	Neurological Disease
PL-017 is a potent and selective μ opioid receptor agonist with an IC₅₀ of 5.5 nM for ¹²⁵I-FK 33,824 binding to μ site. PL-017 produces long-lasting, reversible analgesia in rats .

HY-P1625

Daeatal Dynorphin A ethylamide (1-9)	Opioid Receptor	Neurological Disease
Daeatal (Dynorphin A ethylamide (1-9)) is an ethylamine-modified dynorphin fragment that can be used in the study of analgesia, addiction, depression, etc. Dynorphin A is an endogenous opioid peptide involved in inhibitory neurotransmission in the central nervous system (CNS). Dynorphin A is a highy potent kappa opioid receptor (KOR) agonist, and is also an agonist for other opioid receptors, such as mu (MOR) and delta (DOR). Dynorphin A can induce neuronal death, and can be used in the research of neurological disease .

HY-P1338A

PL-017 TFA	Opioid Receptor	Neurological Disease
PL-017 TFA is a potent and selective μ opioid receptor agonist with an IC₅₀ of 5.5 nM for ¹²⁵I-FK 33,824 binding to μ site. PL-017 TFA produces long-lasting, reversible analgesia in rats .

HY-P0192

[Phe1Ψ(CH2-NH)Gly2]Nociceptin(1-13)NH2	Opioid Receptor	Neurological Disease
[Phe1Ψ(CH2-NH)Gly2]Nociceptin(1-13)NH2 is a nociceptin receptor (ORL1) agonist. [Phe1Ψ(CH2-NH)Gly2]Nociceptin(1-13)NH2 strongly depresses the nociceptive flexor reflex in rats. [Phe1Ψ(CH2-NH)Gly2]Nociceptin(1-13)NH2 can be used for analgesia research .

HY-P5061

Dynorphin A (1-13) amide	Opioid Receptor	Neurological Disease
Dynorphin A (1-13) amide is an endogenous opioid peptide that antagonizes morphine-induced analgesia .

HY-P5899

Mambalgin-3	Sodium Channel	Neurological Disease
Mambalgin-3 is an acid-sensitive ion channel 1 (ASIC1) inhibitor. Mambalgin-3 can be used in the study of analgesia .

HY-P10555

(D-Arg2, Sar 4)-Dermorphin (1-4)	Opioid Receptor	Neurological Disease
(D-Arg2, Sar 4)-Dermorphin (1-4) is a tetrapeptide derivative of the peptide Dermorphin (HY-P0244) found in amphibian skin. (D-Arg2, Sar 4)-Dermorphin (1-4) has significant analgesic effects by binding to the μ-opioid receptor (MOR) in the body. (D-Arg2, Sar 4)-Dermorphin (1-4) can be used in the development of analgesic drugs .

HY-P1198A

Hemokinin 1, human TFA	Neurokinin Receptor	Neurological Disease
Hemokinin 1, human TFA is a selective tachykinin neurokinin 1 (NK1) receptor full agonist. Hemokinin 1, human TFA is a full agonist at NK2 and NK3 receptor. Hemokinin 1, human TFA can produces an opioid-independent analgesia .

HY-P5863

Mambalgin-2 Mamb-2	Sodium Channel	Neurological Disease
Mambalgin-2 (Mamb-2) is an acid-sensitive ion channels (ASICs) inhibitor and a venom peptide. Mambalgin-2 can be obtained from the venom of the African black mamba. Mambalgin-2 can be used in the study of pain and neurological diseases .

HY-P1319A

Nociceptin(1-7) TFA	Opioid Receptor	Inflammation/Immunology
Nociceptin (1-7) TFA is the N-terminal bioactive fragment of nociceptin (HY-P0183). Nociceptin (1-7) TFA is a potent ORL₁ (NOP) receptor agonist with antinociceptive activity. Nociceptin (1-7) TFA combines with nociceptin reduces hyperalgesia in vivo .

Cat. No.	상품명	Target	Research Area	Image

HY-P991622

MNAC13	Trk Receptor	Neurological Disease Inflammation/Immunology
MNAC13 is a kind of mouse IgG1 chimeric antibody, targeting to human TrkA. MNAC13 inhibits the NGF dependent signaling pathway by specifically binding to TrkA receptors. MNAC13 has good analgesic effect and long-lasting efficacy. MNAC13 can be used for researches on inflammatory and chronic pain .

HY-P991325

CRB-0089	Trk Receptor	Inflammation/Immunology
CRB-0089 is a human monoclonal antibody (mAb) targeting NGF/bNGF. CRB-0089 can be used in analgesia research.

Cat. No.	상품명	Category	Target	Chemical Structure

HY-113413

Imidazoleacetic acid 2 Publications Verification Imidazolyl-4-acetic acid	Structural Classification Human Gut Microbiota Metabolites Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite GABA Receptor
Imidazoleacetic acid (Imidazolyl-4-acetic acid) is a blood-brain barrier-permeable full agonist of the GABA_A receptor. Imidazoleacetic acid forms via histamine oxidation in the mouse brain. Imidazoleacetic acid exerts multiple neurochemical and behavioral effects. Imidazoleacetic acid induces a range of centrally mediated effects, including analgesia, sedation, hypnosis, as well as reductions in blood pressure, body temperature, isolation-induced aggression and motor activity .

HY-N7126

Citronellal	Structural Classification Ketones, Aldehydes, Acids Murraya paniculata (L.) Jack. Rutaceae Plants Source Classification	Environmental Pollutants Potassium Channel
Citronellal is a monoterpene that can be found in the essential oils in various aromatic species of plants, with antiinflammatory and antinociceptive properties. Citronellal attenuates mechanical nociception, mediated in part by the NO-cGMP-ATP-sensitive K+ channel pathway. Citronellal induces reduction of spontaneuous activity, ataxia, analgesia, and sedation in vivo. Citronellal can attenuate mechanical nociception response in mouse model .

HY-N3945

Glaucine O,O-Dimethylisoboldine; S-(+)-Glaucine; NSC 34396	Infection Alkaloids other families Classification of Application Fields Plants Isoquinoline Alkaloids Glaucium flavum Inflammation/Immunology Disease Research Fields Papaveraceae Source Classification	Phosphodiesterase (PDE) Calcium Channel MMP NF-κB
Glaucine (O,O-Dimethylisoboldine) is an alkaloid extracted from Glaucium flavum that possesses various activities, including cough relief, bronchodilation, anti-inflammatory effects, analgesia, antipyretic properties, and anticancer effects. Glaucine acts as a selective and orally active inhibitor of phosphodiesterase 4 (PDE4), with a K_i of 3.4 µM in human bronchial tissues and polymorphonuclear leukocytes. Glaucine induces relaxation of human isolated bronchi by antagonizing calcium channels. Additionally, Glaucine inhibits the activation of NF-κB, leading to a reduction in the expression of the MMP-9 gene, thereby suppressing the migration and invasion of breast cancer cells. Therefore, Glaucine holds potential for research in asthma and breast cancer .

HY-N6891

Hamaudol 2 Publications Verification	Monophenols Classification of Application Fields Ophryosporus axilliflorus Hieron. Ketones, Aldehydes, Acids Phenols Plants Umbelliferae Disease Research Fields Inflammation/Immunology Source Classification	COX
Hamaudol is a chromone isolated from Saposhnikovia divaricata. Hamaudol shows significant inhibitory activity on cyclooxygenase (COX)-1 and COX-2 activities with IC₅₀ values of 0.30, 0.57 mM, respectively, and has potent analgesia and anti-inflammary effects .

HY-N15269

Cyperol	Structural Classification Terpenoids Sesquiterpenes Cyperaceae Cyperus rotundus L. Plants Source Classification	Others
Cyperol is a chemical component of the Nagarmotha (Cyperus rotundus). Nagarmotha possesses various pharmacological activities such as diuresis, digestion, menstruation, insect repellent, analgesia and anti-inflammatory .

HY-W162983

3,4-Diphenyl-5H-furan-2-one	Callicarpa cathayana Hung T. Chang Natural Products Acanthaceae Plants Source Classification	COX
3,4-Diphenyl-5H-furan-2-one is a natural compound isolated from the endophytic fungus Aspergillus flavipes AIL8 derived from the mangrove plant Acanthus ilicifolius. 3,4-Diphenyl-5H-furan-2-one is a derivative of 2,3-diphenyltetrahydrofuran (DPTF), which is a COX-2 inhibitor. 3,4-Diphenyl-5H-furan-2-one can be used as a lead compound for inflammation and pain .

HY-N7126R

Citronellal (Standard)	Structural Classification Ketones, Aldehydes, Acids Murraya paniculata (L.) Jack. Rutaceae Plants Source Classification	Reference Standards Potassium Channel
Citronellal (Standard) is the analytical standard of Citronellal. This product is intended for research and analytical applications.Citronellal is a monoterpene that can be found in the essential oils in various aromatic species of plants, with antiinflammatory and antinociceptive properties. Citronellal attenuates mechanical nociception, mediated in part by the NO-cGMP-ATP-sensitive K+ channel pathway. Citronellal induces reduction of spontaneuous activity, ataxia, analgesia, and sedation in vivo. Citronellal can attenuate mechanical nociception response in mouse model .

HY-113413R

Imidazoleacetic acid (Standard) Imidazolyl-4-acetic acid (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite GABA Receptor
Imidazoleacetic acid (Standard) is the analytical standard of Imidazoleacetic acid (HY-113413). This product is intended for research and analytical applications. Imidazoleacetic acid (Imidazolyl-4-acetic acid) is a blood-brain barrier-permeable full agonist of the GABA_A receptor. Imidazoleacetic acid forms via histamine oxidation in the mouse brain. Imidazoleacetic acid exerts multiple neurochemical and behavioral effects. Imidazoleacetic acid induces a range of centrally mediated effects, including analgesia, sedation, hypnosis, as well as reductions in blood pressure, body temperature, isolation-induced aggression and motor activity .

HY-127003

Neoambrosin	Structural Classification Ambrosia maritima L. Terpenoids Diterpenoids Plants Compositae Source Classification	PPAR TRP Channel
Neoambrosin is a sesquiterpene lactone. Neoambrosin acts as a partial agonist of PPARγ and TRPA1 receptors, with no carbonic anhydrase inhibitory activity. Neoambrosin can be used in research on hypoglycemia, analgesia, anti-inflammation and anticancer effects .

Cat. No.	상품명	Chemical Structure

HY-17355BS

Dexpramipexole-d3 dihydrochloride

Dexpramipexole-d₃ ((R)-Pramipexole-d₃) dihydrochloride is the deuterium labeled Dexpramipexole. Dexpramipexole ((R)-Pramipexole) dihydrochloride is an orally active, blood-brain barrier permeable mitochondrial protective agent. Dexpramipexole dihydrochloride upregulates the expression of Parkin, PINK1, GPX4 and FSP1; binds to mitochondrial F1/Fo-ATP synthase; blocks the Na_v1.8 sodium channel; and inhibits the activation of the NLRP3 inflammasome. Dexpramipexole dihydrochloride induces mitophagy, inhibits ferroptosis, pyroptosis, apoptosis, neuroinflammation and eosinophilopoiesis; maintains mitochondrial function and redox homeostasis; reduces reactive oxygen species production; and decreases myocardial infarct size. Dexpramipexole dihydrochloride is applicable to studies on eosinophilic asthma, myocardial ischemia/reperfusion injury, sepsis-associated encephalopathy, analgesia, and more.

HY-17034AS

Dexmedetomidine-13C,d3 hydrochloride

Dexmedetomidine- ¹³C,d₃ (hydrochloride) is the ¹³C- and deuterium labeled Dexmedetomidine (hydrochloride). Dexmedetomidine hydrochloride ((+)-Medetomidine hydrochloride) is a potent, selective and orally active agonist of α2-adrenoceptor, with a K_i of 1.08 nM. Dexmedetomidine hydrochloride shows 1620-fold selectivity against α1-adrenoceptor. Dexmedetomidine hydrochloride exhibits anxiolysis, sedation, and modest analgesia effects .

Cat. No.	상품명		Classification

HY-114759

MS-PPOH 1 Publications Verification		Alkynes
MS-PPOH is a potent and selective cytochrome P450 (CYP) epoxygenase inhibitor . MS-PPOH inhibits CYP2C8 and CYP2C9 with IC₅₀s of 15 and 11 μM, respectively . MS-PPOH is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

온라인 문의

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
호칭			Country or Region *
고객명 *			회사명 *
Department *
메일주소 *			상품명 *
Cat. No.			Requested quantity *
전화번호 *
비고